Synthetic Glycovaccine Protects against the Bite ofLeishmania‐Infected Sand Flies
Author(s) -
Matthew E. Rogers,
О. В. Сизова,
Michael A. J. Ferguson,
Andrei V. Nikolaev,
Paul A. Bates
Publication year - 2006
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/505584
Subject(s) - leishmania , leishmania mexicana , leishmaniasis , biology , immunization , vector (molecular biology) , cutaneous leishmaniasis , virology , phlebotomus , immunology , antigen , microbiology and biotechnology , parasite hosting , biochemistry , world wide web , computer science , gene , recombinant dna
Leishmaniasis is a vectorborne disease transmitted to human and other mammalian hosts by sand fly bite. In the present study, we show that immunization with Leishmania mexicana promastigote secretory gel (PSG) or with a chemically defined synthetic glycovaccine containing the glycans found in L. mexicana PSG can provide significant protection against challenge by the bite of infected sand flies. Only the glycan from L. mexicana was protective; those from other species did not protect against L. mexicana infection. Furthermore, neither PSG nor the glycovaccine protected against artificial needle challenge, which is traditionally used in antileishmanial vaccine development. Conversely, an antigen preparation that was effective against needle challenge offered no protection against sand fly bite. These findings provide a new target for Leishmania vaccine development and demonstrate the critical role that the vector plays in the evaluation of candidate vaccines for leishmaniasis and other vectorborne diseases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom